PEDEvidence
Seletracetam research
Human

Seletracetam: what does this study show?

27 evaluable adults, with 36 exposures because nine returned for another dose. Single oral doses of 0.5, 1, 2, 4, 10 or 20 mg followed a placebo day.

Demonstrated findings

Complete suppression of the light-triggered EEG response occurred in 40–71% of patients, increasing with dose.

Limitations & adverse findings

Single-blind, short-term laboratory response study. Repeated exposures are not independent participants; EEG suppression does not establish cognitive enhancement or long-term clinical benefit.

What might this mean? · interpretation

These findings apply to the population and methods described above.

What might this mean, and what would change the interpretation?

Single-blind, short-term laboratory response study. Repeated exposures are not independent participants; EEG suppression does not establish cognitive enhancement or long-term clinical benefit.

What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.

Findings reviewed · abstract

Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Download evidence card

An editorial reading note with a primary-source link. Interpretation is identified separately from observed results.